CN109810142B - 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 - Google Patents
一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 Download PDFInfo
- Publication number
- CN109810142B CN109810142B CN201910182300.9A CN201910182300A CN109810142B CN 109810142 B CN109810142 B CN 109810142B CN 201910182300 A CN201910182300 A CN 201910182300A CN 109810142 B CN109810142 B CN 109810142B
- Authority
- CN
- China
- Prior art keywords
- ligustrazine
- preparation
- matrine
- mustard
- matrine derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FINHMKGKINIASC-UHFFFAOYSA-N tetramethyl-pyrazine Natural products CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 241000219198 Brassica Species 0.000 title claims abstract description 18
- 235000003351 Brassica cretica Nutrition 0.000 title claims abstract description 18
- 235000003343 Brassica rupestris Nutrition 0.000 title claims abstract description 18
- -1 Nitrogenous mustard ligustrazine matrine derivative Chemical class 0.000 title claims abstract description 18
- 235000010460 mustard Nutrition 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 19
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- 230000001093 anti-cancer Effects 0.000 abstract description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 9
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 9
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 9
- 229930014456 matrine Natural products 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000002633 protecting effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000246044 Sophora flavescens Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- DXOWIETVYMDFIV-UHFFFAOYSA-N ClCCP(=O)(N)CCCl Chemical group ClCCP(=O)(N)CCCl DXOWIETVYMDFIV-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241001145009 Sophora alopecuroides Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- DTHMTBUWTGVEFG-QRPNPIFTSA-N [(1s)-2-methoxy-2-oxo-1-phenylethyl]azanium;chloride Chemical compound Cl.COC(=O)[C@@H](N)C1=CC=CC=C1 DTHMTBUWTGVEFG-QRPNPIFTSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical group ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- SWVMLNPDTIFDDY-SBSPUUFOSA-N methyl (2r)-2-amino-3-phenylpropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=CC=C1 SWVMLNPDTIFDDY-SBSPUUFOSA-N 0.000 description 1
- VEEIFXWJNCAVEQ-RGMNGODLSA-N methyl (2s)-2-amino-3-(1h-imidazol-5-yl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CNC=N1 VEEIFXWJNCAVEQ-RGMNGODLSA-N 0.000 description 1
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 1
- VXYFARNRGZWHTJ-FVGYRXGTSA-N methyl (2s)-2-amino-3-(4-hydroxyphenyl)propanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-FVGYRXGTSA-N 0.000 description 1
- DODCBMODXGJOKD-RGMNGODLSA-N methyl (2s)-2-amino-4-methylpentanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CC(C)C DODCBMODXGJOKD-RGMNGODLSA-N 0.000 description 1
- IYUKFAFDFHZKPI-DFWYDOINSA-N methyl (2s)-2-aminopropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@H](C)N IYUKFAFDFHZKPI-DFWYDOINSA-N 0.000 description 1
- YHYUQHQOUXSXQE-UHFFFAOYSA-N methyl 2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate Chemical compound COC(=O)C(N)CC1=CC=C(N(CCCl)CCCl)C=C1 YHYUQHQOUXSXQE-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000013641 positive control Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910182300.9A CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910182300.9A CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109810142A CN109810142A (zh) | 2019-05-28 |
CN109810142B true CN109810142B (zh) | 2021-09-14 |
Family
ID=66608667
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910182300.9A Active CN109810142B (zh) | 2019-03-12 | 2019-03-12 | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109810142B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083666A (zh) * | 2011-10-28 | 2013-05-08 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN106854223A (zh) * | 2017-01-05 | 2017-06-16 | 石家庄学院 | 氮芥槲皮素衍生物及其制备方法和用途 |
-
2019
- 2019-03-12 CN CN201910182300.9A patent/CN109810142B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103083666A (zh) * | 2011-10-28 | 2013-05-08 | 北京美迪康信医药科技有限公司 | 一种药物组合物及其制剂和用途 |
CN106854223A (zh) * | 2017-01-05 | 2017-06-16 | 石家庄学院 | 氮芥槲皮素衍生物及其制备方法和用途 |
Non-Patent Citations (3)
Title |
---|
抗肿瘤药物的研究 Ⅲ.含氨基酸的氮芥磷酰胺衍生物的合成;宋维良等;《药学学报》;19661231;第13卷(第2期);第126-130页 * |
氮芥型苦参碱衍生物的合成;郑晓辉等;《化学试剂》;20121231;第937-940页 * |
苦参碱-氮芥复合物的合成及抗肿瘤活性研究;崔晓燕等;《化学试剂》;20151231;第37卷;第309-370页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109810142A (zh) | 2019-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112979733B (zh) | 抗乙肝病毒的化合物及其制备方法和应用 | |
CN113480559B (zh) | 一种蒿甲醚衍生物及其制备方法和应用 | |
CN107286220B (zh) | 1,2,4-三氮唑偶联的二氢杨梅素衍生物及其制备方法和应用 | |
CN114380864A (zh) | 一种双氢青蒿素衍生物、制备方法、药物组合物和其在制备抗肿瘤药物中的应用 | |
CN111635449B (zh) | 一种羽扇豆醇吡啶季铵盐衍生物及其制备方法与应用 | |
CN109810142B (zh) | 一种含氮芥川芎嗪苦参碱衍生物及其制备方法和应用 | |
CN111253411B (zh) | 一种小檗碱亚油酸缀合物及其制备方法和用途 | |
CN110642740B (zh) | 异斯特维醇酰胺衍生物及其制备方法 | |
CN113501853B (zh) | 4-硫代尿嘧啶脱氧核苷磷酸酯及其抗病毒药物用途 | |
CN109251196B (zh) | 氨基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 | |
CN113461760B (zh) | 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用 | |
CN107739381B (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
CN113024557B (zh) | 一种Peganumine A生物碱结构简化物及其应用 | |
CN112457365B (zh) | 一类靶向蛋白质水解通路的功能分子及其制备和应用 | |
CN110092789B (zh) | 一种吲哚并[2,3-b]咔唑衍生物及其应用 | |
CN107382944B (zh) | 一类具有抗肿瘤活性的香豆素棉酚衍生物及其合成方法 | |
CN109320552B (zh) | 具有良好生物活性的葛根素衍生物及其制备方法以及应用 | |
CN113880872A (zh) | 一种喜树碱硼酸类化合物的制备及其在抗肿瘤方面的用途 | |
CN108329300B (zh) | 硝基苯并[d]氮杂*基喹唑啉类化合物及其制备方法和应用 | |
CN112142811B (zh) | 一种两亲性菱形超分子金属大环及其制备方法和应用 | |
CN109517025B (zh) | 28-(l-苯丙氨酸)-五环三萜衍生物及其合成方法和应用 | |
CN117343064B (zh) | 一种具有抗病毒作用的嘧啶衍生物的制备与应用 | |
CN111440163B (zh) | 一种含甲氧基取代的1,3,4-噻二唑单元的吡唑化合物及其制备与应用 | |
CN114524847B (zh) | 抗乙型肝炎病毒的化合物及其制备方法和应用 | |
CN114989214B (zh) | 一种紫草素氨基磷酸酯杂合体及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240313 Address after: Room 701, Unit 1, Building 3, No. 169 Zhufeng Street, Yuhua District, Shijiazhuang City, Hebei Province, 050000 Patentee after: Liu Qingfeng Country or region after: China Address before: 050035 Shijiazhuang college, No.6 Changjiang Avenue, high tech Development Zone, Shijiazhuang City, Hebei Province Patentee before: SHIJIAZHUANG University Country or region before: China |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240517 Address after: Room 301, Building A5, Zhongguancun Overseas Science and Technology Park, No. 568 Cangning Road, High tech Zone, Shijiazhuang City, Hebei Province, 050000 Patentee after: Hebei Hegeshan Biotechnology Co.,Ltd. Country or region after: China Address before: Room 701, Unit 1, Building 3, No. 169 Zhufeng Street, Yuhua District, Shijiazhuang City, Hebei Province, 050000 Patentee before: Liu Qingfeng Country or region before: China |